Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
$7.99
-2.6%
$7.66
$6.51
$13.27
$8.47M1.6293,875 shs3,057 shs
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
$1.30
+3.2%
$1.28
$0.85
$4.40
$41.83M0.2931,818 shs16,908 shs
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
$0.86
+3.5%
$0.84
$0.64
$2.26
$34.65M-0.836,883 shs59,839 shs
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
$11.74
+1.5%
$8.09
$2.70
$18.00
$31.77M0.11993,090 shs221,930 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-6.61%-2.80%+6.30%-5.95%-6.39%
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
+1.56%+4.84%-7.14%+44.44%-28.18%
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
+3.87%+3.61%+2.38%-11.44%-61.99%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
+1.47%-4.55%+69.16%+137.65%+1,173,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
2.7011 of 5 stars
3.55.00.00.03.30.80.0
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
3.4527 of 5 stars
3.55.00.00.03.60.81.3
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
3.00
Buy$30.00275.28% Upside
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
3.00
Buy$5.17501.47% Upside
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADXN, BRNS, AKTX, and QNTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/24/2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/21/2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
$404.10K20.97N/AN/A$1.20 per share6.66
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A($0.03) per shareN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
$14.97M2.31N/AN/A$4.85 per share0.18
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/A$21.29 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-$11.76M-$0.34N/AN/A850.30%-112.43%-77.95%6/2/2025 (Estimated)
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
-$10.01MN/A0.00N/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$73.35M-$1.64N/AN/AN/AN/A-34.26%-29.30%8/14/2025 (Estimated)
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$17.90M-$15.98N/AN/AN/AN/A-84.21%-62.63%8/13/2025 (Estimated)

Latest ADXN, BRNS, AKTX, and QNTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/2/2025Q1 2025
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
-$1.4197N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$0.37-$1.41-$1.04-$3.53$2.09 million$2.09 million
5/7/2025Q1 2025
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$0.34-$0.49-$0.15-$0.49N/AN/A
3/28/2025Q4 2024
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
-$0.80-$2.89-$2.09-$2.89$0.92 millionN/A
3/20/2025Q4 2024
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
-$0.50-$0.51-$0.01-$0.51N/A$14.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
N/AN/AN/AN/AN/A
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
N/AN/AN/AN/AN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
N/A
4.59
4.59
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
N/A
0.29
0.29
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
N/A
8.93
8.93
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A
3.76
3.76

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
16.14%
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
5.06%
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
25.20%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
1.24%

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
15.00%
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
38.90%
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
10.70%
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
8.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADXN
Addex Therapeutics
301.06 million901,000Not Optionable
Akari Therapeutics, Plc stock logo
AKTX
Akari Therapeutics
932.18 million16.25 millionNot Optionable
Barinthus Biotherapeutics plc stock logo
BRNS
Barinthus Biotherapeutics
10740.34 million37.01 millionN/A
Quantum Biopharma Ltd. stock logo
QNTM
Quantum Biopharma
N/A2.71 million1.76 millionN/A

Recent News About These Companies

Quantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MS
Quantum BioPharma adds Kevin Malone as advisor
Quantum Group appoints Malone as advisor to Board of Directors
Quantum BioPharma Corporate Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics NASDAQ:ADXN

$7.99 -0.22 (-2.63%)
Closing price 05/28/2025 03:56 PM Eastern
Extended Trading
$8.08 +0.09 (+1.06%)
As of 05/28/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.30 +0.03 (+2.78%)
As of 05/28/2025 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Barinthus Biotherapeutics stock logo

Barinthus Biotherapeutics NASDAQ:BRNS

$0.86 +0.03 (+3.49%)
Closing price 05/28/2025 03:59 PM Eastern
Extended Trading
$0.84 -0.02 (-2.21%)
As of 05/28/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Quantum Biopharma stock logo

Quantum Biopharma NASDAQ:QNTM

$11.74 +0.17 (+1.47%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$11.66 -0.09 (-0.72%)
As of 05/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.